Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 14, Issue 35, 2008, Pages 5419-5427

  Couvert, Philippe ^a,b,c   Carrié, Alain ^a,b,c   Pariès, Jacques ^d   Vaysse, Jenny ^d   Miroglio, Audrey ^e   Kerjean, Antoine ^e   Nahon, Pierre ^d,f   Chelly, Jamel ^e   Trinchet, Jean Claude ^d,f   Beaugrand, Michel ^d,f   Ganne Carrié, Nathalie ^d,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL JEAN VERDIER   (France)

^e INSTITUT COCHIN   (France)

^f UNIVERSITÉ PARIS 13   (France)

Author keywords

Cirrhosis; DNA methylation; Insulin growth factor 2; Liver cancer

Indexed keywords

PROTHROMBIN; SOMATOMEDIN B; DNA; IGF2 PROTEIN, HUMAN; PRIMER DNA;

ADULT; AGE; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; AGED; BLOOD; CHEMISTRY; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HEPATITIS C; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 64849098709     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5419     Document Type: Article

References (57)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285
2. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J. Trends in primary liver cancer. Lancet 1998; 351: 215-216
3. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351: 214-215
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
5. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143
6. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230
7. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-749
8. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259
9. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680
10. Kobayashi K, Sugimoto T, Makino H, Kumagai M, Unoura M, Tanaka N, Kato Y, Hattori N. Screening methods for early detection of hepatocellular carcinoma. Hepatology 1985; 5: 1100-1105
11. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21: 1029-1034
12. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-985
13. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-687
14. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-758
15. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, Osuga T. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31: 552-558
16. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201-205
17. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136
18. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001; 16: 406-415
19. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxi A, Gasbarrini G, Bernardi M. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-848
20. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006; 4: 1062-1068
21. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-945.e4
22. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-1302
23. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862
24. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997; 336: 633-640
25. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137
26. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-693
27. Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem 1997; 122: 717-722
28. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-13784
29. Tsai JF, Jeng JE, Chuang LY, You HL, Ho MS, Lai CS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Yu ML, Dai CY. Serum insulin-like growth factor-II and alphafetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol 2003; 24: 291-298
30. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346
31. Falls JG, Pulford DJ, Wylie AA, Jirtle RL. Genomic imprinting: implications for human disease. Am J Pathol 1999; 154: 635-647
32. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001; 2: 21-32
33. Sohda T, Yun K, Iwata K, Soejima H, Okumura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996; 75: 307-311
34. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988; 48: 6844-6849
35. Aihara T, Noguchi S, Miyoshi Y, Nakano H, Sasaki Y, Nakamura Y, Monden M, Imaoka S. Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology 1998; 28: 86-89
36. Takeda S, Kondo M, Kumada T, Koshikawa T, Ueda R, Nishio M, Osada H, Suzuki H, Nagatake M, Washimi O, Takagi K, Takahashi T, Nakao A, Takahashi T. Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 1996; 12: 1589-1592
37. Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, Nakao A, Takahashi T. Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 1997; 18: 193-198
38. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ, Schirmacher P. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997; 57: 2048-2054
39. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002; 62: 6442-6446
40. Feinberg AP. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 1999; 59: 1743s-1746s
41. Poirier K, Chalas C, Tissier F, Couvert P, Mallet V, Carrie A, Marchio A, Sarli D, Gicquel C, Chaussade S, Beljord C, Chelly J, Kerjean A, Terris B. Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. J Pathol 2003; 201: 473-479
42. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-1755
43. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
44. Couvert P, Poirier K, Carrie A, Chalas C, Jouannet P, Beldjord C, Bienvenu T, Chelly J, Kerjean A. DHPLC-based method for DNA methylation analysis of differential methylated regions from imprinted genes. Biotechniques 2003; 34: 356-362
45. Kaplan E, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958; 53: 457-481
46. Tarone RE. Tests for trend in life table analysis. Biometrika 1975; 62: 679-682
47. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187-220
48. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 2271-2282
49. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-2722
50. Tischoff I, Tannapfe A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1741-1748
51. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K. Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig Dis Sci 1996; 41: 208-215
52. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229-257
53. Cariani E, Seurin D, Lasserre C, Franco D, Binoux M, Brechot C. Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis. J Hepatol 1990; 11: 226-231
54. Cruz-Correa M, Cui H, Giardiello FM, Powe NR, Hylind L, Robinson A, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Feinberg AP. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004; 126: 964-970
55. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-273
56. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586
57. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358